Professor Dr. Britta Siegmund

Vice President of the DFG since 2019

Professor Dr. Britta Siegmund

Professor Dr. Britta Siegmund

Born 25 October 1971

Britta Siegmund is Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charité – Universitätsmedizin Berlin.


W3 professorship, Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charité – Universitätsmedizin Berlin, Medical Director CharitéCenter 13


1992 - 1998Study of Medicine, Ludwig-Maximilians-Universität München 
and Harvard Medical School, Boston
2007Board certificate in Internal Medicine
2009Board certificate in Gastroenterology

Academic degrees

Year Description
1998 Doctorate, Dr. med., Department of Clinical Pharmacology, Ludwig-Maximilians-Universität München (Prof. Dr. S. Endres)
2006 Habilitation, venia legendi, Charité - Universitätsmedizin Berlin (Prof. Dr. M. Zeitz)

Professional and academic career

since 3/2016Medical Director, Charité Center 13 
(Gastroenterology, Nephrology, Metabolic Diseases)
since 2013W3 professor, Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, 
Benjamin Franklin Campus, Charité - Universitätsmedizin Berlin
2012 - 2013Acting Head of Division, Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, 
Benjamin Franklin Campus, Charité - Universitätsmedizin Berlin
2012 - 2013W2 Heisenberg professorship, "Translational Gastroenterology – Inflammatory Bowel Disease"; Charité – Universitätsmedizin Berlin
2007 - 2012Senior physician, Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, 
Benjamin Franklin Campus, Charité - Universitätsmedizin Berlin
2002 - 2007Residency in internal medicine, Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, 
Benjamin Franklin Campus, Charité – Universitätsmedizin Berlin
2000 - 2002DFG research fellowship, Department 
of Infectious Diseases, University of Colorado, Denver, CO, USA 
(Prof. C. A. Dinarello)
1998 - 2000Residency, Department of Medicine, Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität, München 
(Prof. Dr. Dr. h.c. P. Scriba)

Other activities

2023 - 2025President, European Crohn’s & Colitis Organization (ECCO)
2020 - 2023President-Elect, ECCO
since 2019Chair of the Permanent Senate Commission on Key Questions in Clinical Research
since 2019Chair of the Joint Committee of the DFG and Leopoldina on Dealing with Dual Use Research of Concern
since 2019Vice President of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
since 2018Deputy member of the Faculty Council
since 2018Member of the Spokesperson’s Committee of the Advisory Board of the Deutsche Crohn & Colitis Vereinigung (DCCV)
since 2018Co-spokesperson of CRC/Transregio 241 “Immune-Epithelial Communication in Inflammatory Bowel Diseases” 
(Erlangen, Berlin)
since 2018Member of the Advisory Board of EBioMedicine & Nature Review in Gastroenterology & Hepatology
2017 - 2019Member of DFG Senate
since 2017Chair of Berlin-Brandenburg Society of Gastroenterology and Hepatology
2017 - 2022Board member of the German Society of Gastroenterology and Digestive and Metabolic Diseases (DGVS)
2017 - 2021Member of Scientific Committee of United European Gastroenterology (UEG)
2016 - 2021Member of the supervisory board of the Berlin Institute of Health
2016 - 2017Member of DFG review board
2016 - 2023Member of the committee of the United Registries for Clinical Assessment and Research (UR-CARE), ECCO
since 2016Member of Leibniz ScienceCampus Berlin on chronic inflammation
2015 - 2016Member of the advisory board of DGVS
2015 - 2021Associate Editor, Journal of Crohn’s and Colitis
2014 - 2018Member of the advisory board of DCCV
2016 - 2018Member of the research committee of the Berlin Institute of Health
2015 - 2019Member of the supervisory board of Universitätsmedizin Münster, Germany
2014 - 2017Member and, in 2017, chair of the ECCO Scientific Committee
2013 - 2018ECCO National Representative
2012 - 2015Spokesperson for CRC 633 “Induction and Modulation of T cell Mediated Immune Responses in the Gastrointestinal Tract”
since 2012Board member of Intestinal Diseases Network
since 2010Deputy director of Clinician Scientist Program at the Berlin Institute of Health and Charité – Universitätsmedizin Berlin
since 2009Member of the spokesperson committee of the German IBD Study Group
since 2009Faculty member of the International Max Planck Research School for Infectious Diseases and Immunology
2009Chair of German Work Group for Inflammatory Bowel Diseases
2005 - 2011Member of Research Committee, Charité – Universitätsmedizin Berlin


1997Fellowship from the Harvard-Munich Alliance for Medical Education
2000DFG research fellowship
2002Fellowship for Keystone Symposium “Microbial-Epithelial-Lymphocyte Interactions in Mucosal Immunity”
2003 - 2007DFG Emmy Noether independent junior research group
2006Rising Star in Gastroenterology, United European Gastroenterology Federation
2012DFG Heisenberg professorship
since 2017Member of the German National Academy of Sciences Leopoldina
since 2019Member of the Berlin-Brandenburg Academy of Sciences and Humanities
since 2020Member of the Walter-Siegenthaler-Gesellschaft

Reviewer roles


American Journal of Pathology, Biochemical Pharmacology, BMC Gastroenterology, Cancer Letters, Cell & Tissue Research, Current Pharmaceutical Design, Deutsches Ärzteblatt, AP&T, Cell, Cell Metabolism, Cell Reports, Digestion, EMBO Molecular Medicine, Experimental and Clinical Endocrinology & Diabetes, Expert Reviews Immunology, Gastroenterology, Gut, Human Immunology, Human Pathology, Immunity, Inflammatory Bowel Diseases, International Journal of Colorectal Diseases, Journal of Crohn’s and Colitis, Journal of Immunology, Journal of Inflammation, Journal of Molecular Medicine, Lancet, Lancet Gastroenterology & Hepatology, Medizinische Klinik, Nature Reviews in Immunology, Nature Immunology, Nature Communication, Nature Medicine, eLife, PLoS One, Proceedings of the National Academy of Sciences USA, Trends in Immunology, Zeitschrift fur Gastroenterologie

Funding organisations

Agence Nationale de la Recherche, BONFOR Programme, University of Bonn, Crohn’s & Colitis Foundation of America, Czech Health Research Council, Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe (German Cancer Aid), Ethikkommission Wien, European Crohn’s & Colitis Organization, European Research Council, Elis & Edythe Broad Foundation, Flanders Research Foundation, German-Israeli Foundation, INSERM, International Organization for the Study of IBD, Max Rubner Prize, UK Medical Research Council, Netherlands Organisation of Scientific Research (NWO); Research Foundation Flanders, United States – Israel Binational Science Foundation, Swiss National Science Foundation

Third-party funding

Year Description
2003 - 2007 DFG Emmy Noether Programme, SI 749/3-1, SI 749/3-3, SI 749/3-4
2004 - 2006 Elis and Edythe Broad Foundation
2006 - 2013 SI 749/5-1; SI 749/5-3
2007 - 2011 CRC 633, project A12N
2006 - 2009 BMBF, Inflammatory Bowel Disease Network
2011 - 2015 CRC 633, project A12, ZP01
2012 - 2015 DFG Heisenberg professorship, DFG SI 749/6-1
2015 Stiftung Charité, BIH_PRO-318
2013 - 2016 Helmholtz, Preclinical Comprehensive Cancer Center
2013 - 2016 PP 1658 „Intestinal Microbiota“, SI 749/7-1
2015 - 2020 Horizon 2020, SPARE Project (national coordinator)
2015 - 2020 German-Israel Foundation, I-1295-414
2016 - 2019 Deutsche Krebshilfe (German Cancer Aid), 70112011
2016 - 2020 DFG, SI 749/10-1
2016 - 2019 Berlin Institute of Health, „GESPIC-Crohn”-study
2016 - 2029 SPP 1658 „Intestinal Microbiota“, Si 749/9-1
2017 - 2020 DFG, GRK 2318 “Tight Junction Train”
2018 - 2022 DFG, CRC-TRR 241 “Immune-Epithelial Communication in IBD”, B02, Z01
2018 - 2022 DFG, CRC 1340 “Matrix in Vision“, B06

Selected publications

# contributed equally, # open access

  1. Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D’Haens G, Picon L, BossuytP, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. #
  2. Hecker J, Letizia M, Loescher BS, Siegmund B*, Weidinger C*. Early Onset of TNFα-Driven Arthritis, Auto-inflammation, and Progressive Loss of Vision in a Patient with ALPK1 Mutation. J Clin Immunol. 2022 May;42(4):880-884. doi: 10.1007/s10875-022-01214-8. #
  3. Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):544-558. doi: 10.1038/s41575-021-00424-6.
  4. Jessen B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, Kruglov A, Freise I, Schmidt F, Maul J, Kühl AA, Glauben R, Lissner D*, Siegmund B*. Level of Tumour Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. Clin Gastroenterol Hepatol. 2021 Apr;19(4):721-731.e1. doi: 10.1016/j.cgh.2020.03.066.
  5. Ziegler JF, Böttcher C, Letizia M, Yerinde C, Wu H, Freise I, Rodriguez-Sillke Y, Stoyanova AK, Kreis ME, Asbach P, Kunkel D, Priller J, Anagnostopoulos I, Kühl AA, Miehle K, Stumvoll M, Tran F, Fredrich B, Forster M, Franke A, Bojarski C, Glauben R, Löscher BS, Siegmund B*, Weidinger C*. Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and combined Crohn’s disease. Nat Commun. 2019 Dec 10;10(1):5629. doi: 10.1038/s41467-019-13559-7. #
  6. Wu H, Han Y, Rodriguez Sillke Y, Deng H, Siddiqui S, Treese C, Schmidt F, Friedrich M, Keye J, Wan J, Qin Y, Kühl AA, Qin Z, Siegmund B*, Glauben R*. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumour-associated macrophages. EMBO Mol Med. 2019 Nov 7;11(11):e10698. doi: 10.15252/emmm.201910698. #
  7. Kredel LI, Jödicke LJ, Scheffold A, Gröne J, Glauben R, Erben U, Kühl AA, Siegmund B. T-cell composition in ileal and colonic creeping fat – separating ileal from colonic Crohn’s disease. J Crohns Colitis, 2019, 13(1):79-91. doi: 10.1093/ecco-jcc/jjy146. #
  8. Kredel LI, Batra A, Stroh T, Kühl AA, Zeitz M, Erben U, Siegmund B. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013 Jun;62(6):852- 62. doi: 10.1136/gutjnl-2011-301424. #
  9. Siegmund B, Sennello JA, Jones-Carson J, Gamboni-Robertson F, Lehr HA, Batra A, Fedke I, Zeitz M, Fantuzzi G. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut. 2004 Jul;53(7):965-72. doi: 10.1136/gut.2003.027136. #
  10. Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology. 2002 Jun;122(7):2011-25. doi: 10.1053/gast.2002.33631.